Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...
Annexon (NASDAQ:ANNX) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline a set of ...
Company sharpens focus on high-margin, recurring-revenue technology-enabled services while selectively pursuing AI-adjacent and GPU-oriented opportunities ...
Regeneron's strategy focuses on a broad pipeline across six therapeutic areas, with significant near-term data readouts ...
Ocugen has announced the publication of positive results from its phase 1 GARDian1 trial of OCU410ST, a gene therapy for ...
A new study published in the prestigious journal Nature in collaboration with a researcher from the University of Bucharest ...
Randomized clinical trials remain the gold standard for establishing a medication's effects, producing the evidence by which ...
Meta Platforms has entered into partnerships with nuclear energy companies Oklo and Constellation Energy to secure long term ...
SAN DIEGO--(BUSINESS WIRE)--Teradata (NYSE: TDC) today announced that HCA Healthcare is moving certain operational data and analytic workloads to Teradata VantageCloud on Google Cloud as part of its ...
New online platform provides evidence-based protection guidance for families, schools, and businesses amid escalating digital dangers The cyber threats facing UK families, schools, and businesses in ...
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback